Trial Profile

A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary) ; Topotecan (Primary)
Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Gallbladder cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Rectal cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

13 Apr 2025 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
12 Apr 2021 According to a Merck AG media release, results from this study were published in Cancer Cell.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com